DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 44.19 Billion KRW | 149.85% |
| 2022 | 17.68 Billion KRW | -49.18% |
| 2021 | 34.8 Billion KRW | 2.63% |
| 2020 | 33.91 Billion KRW | 440.1% |
| 2019 | -9.97 Billion KRW | -53.03% |
| 2018 | -6.51 Billion KRW | 88.59% |
| 2017 | -57.13 Billion KRW | -7.63% |
| 2016 | -53.08 Billion KRW | -71.85% |
| 2015 | -30.88 Billion KRW | -52.01% |
| 2014 | -20.31 Billion KRW | -106.67% |
| 2013 | -9.83 Billion KRW | -20.96% |
| 2012 | -8.12 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 44.61 Billion KRW | 2.45% |
| 2024 Q1 | 43.55 Billion KRW | -1.45% |
| 2023 Q3 | 43.89 Billion KRW | -32.5% |
| 2023 Q4 | 44.19 Billion KRW | 0.69% |
| 2023 FY | 44.19 Billion KRW | 149.85% |
| 2023 Q1 | 62.36 Billion KRW | 252.56% |
| 2023 Q2 | 65.02 Billion KRW | 4.27% |
| 2022 Q1 | 33.96 Billion KRW | -2.42% |
| 2022 Q3 | 72.11 Billion KRW | 34.99% |
| 2022 Q2 | 53.42 Billion KRW | 57.28% |
| 2022 FY | 17.68 Billion KRW | -49.18% |
| 2022 Q4 | 17.68 Billion KRW | -75.47% |
| 2021 Q4 | 34.8 Billion KRW | -16.38% |
| 2021 Q1 | 52.8 Billion KRW | 361.94% |
| 2021 FY | 34.8 Billion KRW | 2.63% |
| 2021 Q2 | 56.93 Billion KRW | 7.81% |
| 2021 Q3 | 41.62 Billion KRW | -26.88% |
| 2020 Q4 | 11.43 Billion KRW | 105.58% |
| 2020 Q3 | 5.56 Billion KRW | -88.48% |
| 2020 FY | 33.91 Billion KRW | 440.1% |
| 2020 Q1 | -268.03 Million KRW | 97.31% |
| 2020 Q2 | 48.25 Billion KRW | 18101.25% |
| 2019 Q4 | -9.97 Billion KRW | 55.99% |
| 2019 Q1 | -17.1 Billion KRW | -162.44% |
| 2019 Q2 | -25.83 Billion KRW | -51.08% |
| 2019 Q3 | -22.65 Billion KRW | 12.31% |
| 2019 FY | -9.97 Billion KRW | -53.03% |
| 2018 Q2 | -54.74 Billion KRW | 9.29% |
| 2018 FY | -6.51 Billion KRW | 88.59% |
| 2018 Q4 | -6.51 Billion KRW | 86.03% |
| 2018 Q3 | -46.64 Billion KRW | 14.79% |
| 2018 Q1 | -60.34 Billion KRW | -13.31% |
| 2017 Q4 | -53.25 Billion KRW | -8.98% |
| 2017 FY | -57.13 Billion KRW | -7.63% |
| 2017 Q1 | -54.51 Billion KRW | -7.44% |
| 2017 Q2 | -54.14 Billion KRW | 0.69% |
| 2017 Q3 | -48.86 Billion KRW | 9.74% |
| 2016 Q2 | -34.92 Billion KRW | 0.79% |
| 2016 FY | -53.08 Billion KRW | -71.85% |
| 2016 Q1 | -35.2 Billion KRW | -23.15% |
| 2016 Q3 | -45.1 Billion KRW | -29.16% |
| 2016 Q4 | -50.74 Billion KRW | -12.5% |
| 2015 Q2 | -18.04 Billion KRW | 1.99% |
| 2015 FY | -30.88 Billion KRW | -52.01% |
| 2015 Q3 | -15.47 Billion KRW | 14.22% |
| 2015 Q1 | -18.4 Billion KRW | 9.41% |
| 2015 Q4 | -28.58 Billion KRW | -84.71% |
| 2014 FY | -20.31 Billion KRW | -106.67% |
| 2014 Q1 | -16.59 Billion KRW | -68.83% |
| 2014 Q3 | -20.32 Billion KRW | -77.73% |
| 2014 Q2 | -11.43 Billion KRW | 31.12% |
| 2014 Q4 | -20.31 Billion KRW | 0.02% |
| 2013 Q3 | -7.83 Billion KRW | -26.66% |
| 2013 FY | -9.83 Billion KRW | -20.96% |
| 2013 Q2 | -6.18 Billion KRW | 4.38% |
| 2013 Q4 | -9.83 Billion KRW | -25.41% |
| 2013 Q1 | -6.47 Billion KRW | 20.36% |
| 2012 FY | -8.12 Billion KRW | 0.0% |
| 2012 Q3 | -5.12 Billion KRW | 0.0% |
| 2012 Q4 | -8.12 Billion KRW | -58.75% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | -133.077% |
| CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | -135.274% |
| Celltrion Pharm, Inc. | 142.81 Billion KRW | 69.055% |
| Huons Global Co., Ltd. | 13.26 Billion KRW | -233.166% |
| Enzychem Lifesciences Corporation | -9.81 Billion KRW | 550.353% |
| Humedix Co., Ltd. | -77.54 Billion KRW | 156.991% |
| Boditech Med Inc. | -31.92 Billion KRW | 238.426% |
| EuBiologics Co., Ltd. | 4.88 Billion KRW | -805.342% |
| FutureChem Co.,Ltd | -4.93 Billion KRW | 996.322% |
| Huons Co., Ltd. | 73.9 Billion KRW | 40.205% |
| BNC Korea Co., Ltd. | -67.65 Billion KRW | 165.327% |
| AptaBio Therapeutics Inc. | -12.08 Billion KRW | 465.778% |